Standard valve event-free (%) | Silzone valve event-free (%) | Standard − Silzone (% and 95% CI) | |||||||
---|---|---|---|---|---|---|---|---|---|
3 m | 1 y | 3 y | 3 m | 1 y | 3 y | 3 m | 1 y | 3 y | |
*There was one case of probable endocarditis in the standard group, as assessed by the Duke criteria. | |||||||||
CI, confidence interval; m, months; y, years. | |||||||||
All thromboembolism | 97 | 93 | 85 | 94 | 91 | 88 | 3 (−6 to 12) | 2 (−10 to 14) | −3 (−19 to13) |
Major thromboembolism | 100 | 100 | 97 | 97 | 97 | 97 | 3 (−3 to 9) | 3 (−3 to 9) | 0 (−8 to 8) |
Major bleed | 100 | 100 | 92 | 100 | 91 | 84 | 0 (0 to 0) | 9 (−1 to 19) | 8 (−8 to 24) |
Endocarditis* | 99 | 99 | 99 | 100 | 100 | 100 | −1 (−3 to 1) | −1 (−3 to 1) | −1 (−3 to 1) |
Reoperation | 100 | 100 | 98 | 100 | 100 | 100 | 0 (0 to 0) | 0 (0 to 0) | −2 (−5 to 1) |
Death | 99 | 97 | 94 | 100 | 100 | 91 | −1 (−3 to 1) | −3 (−7 to 1) | 3 (−9 to 15) |